$20M VSL Pharmaceuticals probiotic class action settlement
Who qualifies
The class action settlement benefits consumers who purchased VSL#3 in the United States between June 1, 2016, and June 19, 2019.
Where: Nationwide / see notice
Proof needed
Purchase receipts, online receipts or credit card statements
About this settlement
VSL Pharmaceuticals has agreed to a $20 million class action settlement to resolve claims it falsely advertised the VSL#3 probiotic as clinically proven to treat certain medical conditions. The VSL#3 settlement benefits consumers who purchased VSL#3 in the United States between June 1, 2016, and June 19, 2019. Plaintiffs in the class action lawsuit claim VSL Pharmaceuticals falsely advertised the VSL#3 probiotics as clinically proven to treat certain medical conditions. As a result of this false advertising, consumers allegedly overpaid for the product. VSL Pharmaceuticals has not admitted an…
Details
- Case
- Starr v. Pharmaceuticals Inc., Case No. 8:19-cv-02173-LKG, in the U.S. District Court for the District of Maryland
- Administrator
- VSL#3 Class Action c/o Settlement Administrator
- Settlement fund
- $20M
- Seen on
- Discuss in
- Healthcare
Settlement Owl is a discovery tool, not a law firm or settlement administrator. Eligibility is decided solely by the official class definition — confirm every detail on the official settlement website before filing. Payout figures are estimates set by the settlement and may be reduced pro rata.